Download PDF
Exp Clin Endocrinol Diabetes 2018; 126(06): 367-370
DOI: 10.1055/s-0043-118748
Article
© Georg Thieme Verlag KG Stuttgart · New York

The Oral Dipeptidyl-Peptidase-4 Inhibitor Sitagliptin Increases Circulating Levels Of Stromal-Derived Factor-1 Alpha

Athanasia K. Papazafiropoulou
1   Diabetes Centre, First Department of Internal Medicine, Tzaneio Hospital of Piraeus, Piraeus, Greece
,
Nikolaos Papanas
2   Diabetes Centre, Second Department of Internal Medicine, Democritus University of Thrace, Alexandroupolis, Greece
,
Aikaterini Trikkalinou
1   Diabetes Centre, First Department of Internal Medicine, Tzaneio Hospital of Piraeus, Piraeus, Greece
,
Evaggelos Fousteris
1   Diabetes Centre, First Department of Internal Medicine, Tzaneio Hospital of Piraeus, Piraeus, Greece
,
Andreas Melidonis
1   Diabetes Centre, First Department of Internal Medicine, Tzaneio Hospital of Piraeus, Piraeus, Greece
› Author Affiliations
Further Information

Publication History

received 01 May 2017
revised 10 July 2017

accepted 22 August 2017

Publication Date:
20 September 2017 (online)

Also available at
    Permissions and Reprints

Abstract

Recent studies have demonstrated that stromal derived factor-1α (SDF-1α) is a substrate of dipeptidyl-peptidase-4 (DPP-4) inhibitors. It has also been shown that SDF-1α shares anti-apoptotic as well as nephroprotective properties and exerts a beneficial effect in the cardiovascular system. Therefore, the aim of this study was to estimate the effect of treatment with the DDP-4 inhibitor sitagliptin on SDF-1α levels in subjects with type 2 diabetes mellitus (T2D). Overall, 32 patients (16 males) with T2D, mean age (±SD) 67.2±8.3 years, HbA1c 6.4±0.5%, body-mass index (BMI) 29.1±4.9 Kg/m2, T2D duration 8.5±4.0 years receiving metformin monotherapy (17 participants) or metformin plus sitagliptin (15 participants) without known cardiovascular disease were enrolled. Patients on metformin plus sitagliptin exhibited higher plasma levels of SDF-1α compared with those on metformin monotherapy (19.6±4.1 versus 6.9±1.3 pg/ml, respectively, p=0.01). Multivariate regression analysis after controlling for age, sex, body-mass index, smoking, arterial hypertension, dyslipidaemia and other confounders showed that SDF-1α levels were positively correlated with DPP-4 inhibitor treatment (beta=0.91, p=0.001), and negatively with T2D duration (beta=− 0.42, p=0.05), ΗDL-cholesterol levels (beta=− 0.46, p=0.02) and HbA1c (beta=− 0.41, p=0.05). In conclusion, these results suggest that sitagliptin treatment may exert a favourable effect on SDF-1α levels.

Key words

DPP-4 inhibitiors - sitagliptin - stromal derived factor-1α - treatment - type 2 diabetes
 

  • References

  • 1 Drucker DJ. Dipeptidyl peptidase-4 inhibition and the treatment of type 2 diabetes: Preclinical biology and mechanisms of action. Diabetes Care 2007; 30: 1335-1343
    CrossrefPubMedGoogle Scholar
  • 2 Aroor AR, Sowers JR, Jia G. et al. Pleiotropic effects of the dipeptidylpeptidase-4 inhibitors on the cardiovascular system. Am J Physiol Heart Circ Physiol 2014; 307: H477-H492
    CrossrefPubMedGoogle Scholar
  • 3 Kim HS, Shin JA, Lee SH. et al. A comparative study of the effects of a dipeptidyl peptidase-IV inhibitor and sulfonylurea on glucose variability in patients with type 2 diabetes with inadequate glycemic control on metformin. Diabetes Technol Ther 2013; 15: 810-816
    CrossrefPubMedGoogle Scholar
  • 4 Derosa G, Bonaventura A, Bianchi L. et al. Vildagliptin compared to glimepiride on post-prandial lipemia and on insulin resistance in type 2 diabetic patients. Metabolism 2014; 63: 957-967
    CrossrefPubMedGoogle Scholar
  • 5 Koren S, Shemesh-Bar L, Tirosh A. et al. The effect of sitagliptin versus glibenclamide on arterial stiffness, blood pressure, lipids, and inflammation in type 2 diabetes mellitus patients. Diabetes Technol Ther 2012; 14: 561-567
    CrossrefPubMedGoogle Scholar
  • 6 Scirica BM, Bhatt DL, Braunwald E. et al. Saxagliptin and cardiovascular outcomes in patients with type 2 diabetes mellitus. N Engl J Med 2013; 369: 1317-1326
    CrossrefPubMedGoogle Scholar
  • 7 White WB, Cannon CP, Heller SR. et al. Alogliptin after acute coronary syndrome in patients with type 2 diabetes. N Engl J Med 2013; 369: 1327-1335
    CrossrefPubMedGoogle Scholar
  • 8 Green JB, Bethel MA, Armstrong PW. et al. Effect of Sitagliptin on Cardiovascular Outcomes in Type 2 Diabetes. N Engl J Med 2015; 373: 232-242
    CrossrefPubMedGoogle Scholar
  • 9 Fadini GP, Boscaro E, Albiero M. et al. The oral dipeptidyl peptidase-4 inhibitor sitagliptin increases circulating endothelial progenitor cells in patients with type 2 diabetes: Possible role of stromal-derived factor-1alpha. Diabetes Care 2010; 33: 1607-1609
    CrossrefPubMedGoogle Scholar
  • 10 Proost P, Struyf S, Schols D. et al. Processing by CD26/dipeptidyl-peptidase IV reduces the chemotactic and anti-HIV-1 activity of stromal-cell-derived factor-1alpha. FEBS Lett 1998; 432: 73-76
    CrossrefPubMedGoogle Scholar
  • 11 Yano T, Liu Z, Donovan J. et al. Stromal cell derived factor-1 (SDF-1)/CXCL12 attenuates diabetes in mice and promotes pancreatic beta-cell survival by activation of the prosurvival kinase Akt. Diabetes 2007; 56: 2946-2957
    CrossrefPubMedGoogle Scholar
  • 12 Stokman G, Stroo I, Claessen N. et al. SDF-1 provides morphological and functional protection against renal ischaemia/reperfusion injury. Nephrol Dial Transplant 2010; 5: 3852-3859
    PubMedGoogle Scholar
  • 13 Fadini GP, Avogaro A. Dipeptidyl peptidase-4 inhibition and vascular repair by mobilization of endogenous stem cells in diabetes and beyond. Atherosclerosis 2013; 229: 23-29
    CrossrefPubMedGoogle Scholar
  • 14 Subramanian S, Liu C, Aviv A. et al. Stromal cell-derived factor 1 as a biomarker of heart failure and mortality risk. Arterioscler Thromb Vasc Biol 2014; 34: 2100-2105
    CrossrefPubMedGoogle Scholar
  • 15 Huang CY, Shih CM, Tsao NW. et al. Dipeptidyl peptidase-4 inhibitor improves neovascularization by increasing circulating endothelial progenitor cells. Br J Pharmacol 2012; 167: 1506-1519
    CrossrefPubMedGoogle Scholar
  • 16 Shih CM, Chen YH, Lin YW. et al. MK-0626, a dipeptidyl peptidase-4 inhibitor, improves neovascularization by increasing both the number of circulating endothelial progenitor cells and endothelial nitric oxide synthetase expression. Curr Med Chem 2014; 21: 2012-2022
    CrossrefPubMedGoogle Scholar
  • 17 Fadini GP, Bonora BM, Cappellari R. et al. Acute effects of linagliptin on progenitor cells, monocyte phenotypes, and soluble mediators in type 2 diabetes. J Clin Endocrinol Metab 2016; 101: 748-756
    CrossrefPubMedGoogle Scholar
  • 18 Yorifuji N, Inoue T, Iguchi M. et al. The dipeptidyl peptidase-4 inhibitor sitagliptin suppresses mouse colon tumorigenesis in type 2 diabetic mice. Oncol Rep 2016; 35: 676-682
    CrossrefPubMedGoogle Scholar
  • 19 Fujita H, Taniai H, Murayama H. et al. DPP-4 inhibition with alogliptin on top of angiotensin II type 1 receptor blockade ameliorates albuminuria via up-regulation of SDF-1α in type 2 diabetic patients with incipient nephropathy. Endocr J 2014; 61: 159-166
    CrossrefPubMedGoogle Scholar
  • 20 Dei Cas A, Spigoni V, Cito M. et al. Vildagliptin, but not glibenclamide, increases circulating endothelial progenitor cell number: A 12-month randomized controlled trial in patients with type 2 diabetes. Cardiovasc Diabetol 2017; 16: 27
    CrossrefPubMedGoogle Scholar
  • 21 Park KS, Kwak S, Cho YM. et al. Vildagliptin reduces plasma stromal cell-derived factor-1α in patients with type 2 diabetes compared with glimepiride. J Diabetes Investig 2017; 8: 218-826
    CrossrefPubMedGoogle Scholar
  • 22 Aso Y, Jojima T, Iijima T. et al. Sitagliptin, a dipeptidyl peptidase-4 inhibitor, increases the number of circulating CD34(+)CXCR4(+) cells in patients with type 2 diabetes. Endocrine 2015; 50: 659-664
    CrossrefPubMedGoogle Scholar
  • 23 Hristov M, Zernecke A, Bidzhekov K. et al. Importance of CXC chemokine receptor 2 in the homing of human peripheral blood endothelial progenitor cells to sites of arterial injury. Circ Res 2007; 100: 590-597
    CrossrefPubMedGoogle Scholar
  • 24 Li M, Yu J, Li Y. et al. CXCR4 positive bone mesenchymal stem cells migrate to human endothelial cell stimulated by ox-LDL via SDF-1alpha/CXCR4 signaling axis. Exp Mol Pathol 2010; 88: 250-255
    CrossrefPubMedGoogle Scholar
  • 25 Abi-Younes S, Sauty A, Mach F. et al. The stromal cell-derived factor-1 chemokine is a potent platelet agonist highly expressed in atherosclerotic plaques. Circ Res 2000; 86: 131-138
    CrossrefPubMedGoogle Scholar
  • 26 Brenner C, Franz WM, Kόhlenthal S. et al. DPP-4 inhibition ameliorates atherosclerosis by priming monocytes into M2 macrophages. Int J Cardiol 2015; 199: 163-169
    CrossrefPubMedGoogle Scholar
  • 27 Mehta NN, Matthews GJ, Krishnamoorthy P. et al. Higher plasma CXCL12 levels predict incident myocardial infarction and death in chronic kidney disease: Findings from the Chronic Renal Insufficiency Cohort study. Eur Heart J 2014; 35: 2115-2122
    CrossrefPubMedGoogle Scholar
  • 28 Papanas N, Maltezos E. Antidiabetic treatment: Though lovers be lost, love shall not. World J Diabetes 2012; 3: 158-160
    CrossrefPubMedGoogle Scholar
  • 29 Dhamodharan U, Viswanathan V, Krishnamoorthy E. et al. Genetic association of IL-6, TNF-α and SDF-1 polymorphisms with serum cytokine levels in diabetic foot ulcer. Gene 2015; 565: 62-67
    CrossrefPubMedGoogle Scholar
  • 30 Kočí Z, Turnovcová K, Dubský M. et al. Characterization of human adipose tissue-derived stromal cells isolated from diabetic patient's distal limbs with critical ischemia. Cell Biochem Funct 2014; 32: 597-604
    CrossrefPubMedGoogle Scholar